New ultrasound technique aims to spot cancer more clearly
NCT ID NCT07225114
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new ultrasound imaging method called Contrast Enhanced Super-Resolution (CESR) to see if it can better detect and tell apart cancerous and non-cancerous lesions in the breast, liver, and kidney. It involves 40 participants: 10 healthy volunteers to fine-tune the imaging, and 30 patients with known lesions who will receive an IV contrast agent during the scan. The results will be compared to standard ultrasound and biopsy findings to see if this technique improves diagnosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
perflutren lipid contrast agent
What this could lead to
If successful, this could provide a more accurate, non-invasive way to detect and distinguish cancerous lesions in the breast, liver, and kidney.
What could go wrong
This is a small, early-phase study with only 40 participants. The new imaging technique may not prove more accurate than standard ultrasound, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of North Carolina
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact